KRAS and neoplasm: Molecular analysis revealed 8/9 (89%) had tumor-specific deleterious variants in genes of the MAP kinase pathway (7 KRAS and 1 ERBB2), and 8/9 (89%) had TP53 variants (Supplementary Fig. S2).